Intellectual property
More’s the Pity – Rules on Distinctiveness
17 April 2019 - Posted by: David Stone
A recent General Court decision emphasises the difficulty of registering slogans as trade marks, including for specialised medical devices. Medrobotics Corp had applied for registration of SEE MORE. REACH MORE. TREAT MORE. as an EU trade mark (Medrobotics v EUIPO T-555/18) in relation to articulated arms and probes for medical diagnostic and surgical use. Medrobotics’ › Read More
25 March 2019 - Posted by: Rafi Allos
In Boehringer Ingelheim v Generics,* the English High Court ordered the rarely-used remedy of pre-action inspection of property, for the purpose of allowing experiments needed to assess patent infringement. The case provides a useful reminder of the powers of the Court in this area, as well as providing a reference as to how the Court › Read More
23 February 2019 - Posted by: Anna-Maria Withagen
On 14 February 2019, the European Court of Justice (ECJ) published its preliminary ruling related to the policy of the Dutch Medicines Evaluation Board (College ter Beoordeling van Geneesmiddelen – CBG) concerning the limitation of a market authorisation (MA) upon a request of a generic producer for a carve-out of the patented indications in the › Read More
Key developments in relation to new Chinese IP tribunal rule and Chinese patent law amendment
18 January 2019 - Posted by: David Shen
Recently, there have been some key developments in the intellectual property sphere in China that may be relevant to life sciences clients. Below we report on the new Chinese IP tribunal rule and an important Chinese patent law amendment. New Chinese IP tribunal rule The Standing Committee of the National People’s Congress previously announced the › Read More
09 January 2019 - Posted by: Toby Sears
The Opinion of Advocate General Saugmandsgaard Øe in Abraxis Bioscience (Case C-443/17) was delivered on 13 December 2018. The Advocate General concluded that the UK Intellectual Property Office had been correct in declining to grant a Supplementary Protection Certificate (SPC) to Abraxis for a novel formulation of an active substance which had already been the › Read More